Halozyme Therapeutics, Inc. (FRA:RV7)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 19, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	7,110	6,741	5,875	4,417	7,199	4,976
Market Cap Growth	1.03%	14.73%	33.01%	-38.64%	44.69%	5.58%
Enterprise Value	8,837	7,453	6,714	5,364	8,365	5,031
Last Close Price	60.96	58.26	45.93	33.40	53.15	35.71
PE Ratio	26.34	24.98	13.70	17.34	38.06	14.05
PS Ratio	5.98	5.67	5.99	5.89	11.66	12.76
PB Ratio	171.02	162.13	16.72	58.26	45.31	28.73
P/TBV Ratio	-	-	-	-	-	28.73
P/FCF Ratio	12.95	12.28	12.99	13.08	32.70	18.99
P/OCF Ratio	12.81	12.15	12.70	12.57	32.04	18.90
EV/Sales Ratio	7.45	6.27	6.85	7.15	13.54	12.91
EV/EBITDA Ratio	11.48	9.75	11.09	14.22	26.60	20.63
EV/EBIT Ratio	12.75	10.72	12.61	17.56	30.89	20.74
EV/FCF Ratio	16.10	13.58	14.84	15.88	37.99	19.20
Debt / Equity Ratio	44.60	44.60	4.14	18.27	9.07	4.47
Debt / EBITDA Ratio	2.40	2.40	2.38	3.59	4.54	3.15
Debt / FCF Ratio	3.38	3.38	3.22	4.10	6.55	2.95
Net Debt / Equity Ratio	41.68	41.68	2.50	14.26	6.94	0.70
Net Debt / EBITDA Ratio	2.27	2.27	1.45	2.87	3.51	0.50
Net Debt / FCF Ratio	3.16	3.16	1.94	3.20	5.01	0.47
Asset Turnover	0.61	0.61	0.54	0.46	0.45	0.53
Inventory Turnover	1.95	1.95	1.77	2.36	2.67	2.04
Quick Ratio	3.30	3.30	6.50	5.07	4.54	7.10
Current Ratio	4.66	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	153.59%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	22.24%	22.24%	18.16%	11.80%	12.28%	20.47%
Return on Invested Capital (ROIC)	32.36%	33.01%	34.44%	20.77%	27.92%	105.98%
Return on Capital Employed (ROCE)	34.80%	34.80%	28.70%	20.80%	16.90%	27.90%
Earnings Yield	3.80%	4.00%	7.30%	5.77%	2.63%	7.12%
FCF Yield	7.72%	8.14%	7.70%	7.65%	3.06%	5.27%
Buyback Yield / Dilution	4.26%	4.26%	3.56%	4.56%	4.21%	-3.77%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.